LEXX (Lexaria Bioscience) Debt-to-Revenue : 0.41 (As of Aug. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Lexaria Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $0.03 Mil. Lexaria Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $0.11 Mil. Lexaria Bioscience's annualized Revenue for the quarter that ended in Aug. 2024 was $0.34 Mil. Lexaria Bioscience's annualized Debt-to-Revenue for the quarter that ended in Aug. 2024 was 0.41.

Lexaria Bioscience Debt-to-Revenue Historical Data

The historical data trend for Lexaria Bioscience's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Debt-to-Revenue Chart

Lexaria Bioscience Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Debt-to-Revenue

Get a 7-Day Free Trial

0.41

0.13

0.20

0.73

0.30

Lexaria Bioscience Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Debt-to-Revenue	Get a 7-Day Free Trial															1.32	0.26	0.26	0.42	0.41

Competitive Comparison of Lexaria Bioscience's Debt-to-Revenue

For the Biotechnology subindustry, Lexaria Bioscience's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Debt-to-Revenue falls into.

Lexaria Bioscience Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Lexaria Bioscience's Debt-to-Revenue for the fiscal year that ended in Aug. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.028	+	0.109)	/	0.464
	=	0.30

Lexaria Bioscience's annualized Debt-to-Revenue for the quarter that ended in Aug. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.028	+	0.109)	/	0.336
	=	0.41

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Aug. 2024) Revenue data.

Lexaria Bioscience Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6